An open study of botulinum-A toxin treatment of trigeminal neuralgia.
Thirteen subjects with trigeminal neuralgia were treated with botulinum-A neurotoxin (BoNT/A) in an open-label pilot study. After BoNT/A, visual analog scale score, surface area of pain, and therapeutic coefficient were reduced in all patients and for all branch trigeminal nerves studied. Therefore, BoNT/A is an efficient treatment. There were no major side effects. A placebo-controlled clinical trial is needed to confirm these findings.
Piovesan
E J
EJ
Neurology Division, Internal Medicine Department, Hospital de Clinicas, Universidade Federal do Parana, Curitiba, Brazil. piovesan1@hotmail.com
Teive
H G
HG
Kowacs
P A
PA
Della Coletta
M V
MV
Werneck
L C
LC
Silberstein
S D
SD
D000368:Aged; D000700:Analgesics / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use; D001763:Blepharoptosis / Q000139:chemically induced; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009479:Neuropeptides / Q000037:antagonists & inhibitors / Q000378:metabolism; D009498:Neurotoxins / Q000008:administration & dosage / Q000009:adverse effects; D009619:Nociceptors / Q000187:drug effects / Q000502:physiology; D010147:Pain Measurement / Q000187:drug effects; D017288:Pain Threshold / Q000187:drug effects / Q000502:physiology; D010865:Pilot Projects; D011984:Sensory Receptor Cells / Q000187:drug effects / Q000502:physiology; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology; D016896:Treatment Outcome; D014276:Trigeminal Nerve / Q000187:drug effects* / Q000503:physiopathology; D014277:Trigeminal Neuralgia / Q000188:drug therapy* / Q000503:physiopathology
D000700:Analgesics; D000927:Anticonvulsants; D009479:Neuropeptides; D009498:Neurotoxins; D019274:Botulinum Toxins, Type A